Phase I trial demonstrated safety profile and clinical benefit in HER-altered cancers, suggesting metabolic interactions are crucial.
Combination therapy with neratinib and palbociclib demonstrated a favorable safety profile and clinical benefit rate in patients with HER-driven alterations. Pharmacokinetic analysis revealed a CYP3A4-mediated drug-drug interaction, leading to reduced clearance and increased plasma exposure of both agents, underscoring the importance of considering metabolic interactions in future clinical development.
No takes yet. Share an insight, caveat, or question.
Piha-Paul et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: